Citius Pharmaceuticals (CTXR) Competitors $1.93 -0.18 (-8.53%) Closing price 04:00 PM EasternExtended Trading$1.96 +0.03 (+1.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. INCR, IGMS, IMUX, IZTC, IKNA, MNOV, ADAP, ICCC, VHAQ, and CLSDShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include InterCure (INCR), IGM Biosciences (IGMS), Immunic (IMUX), Invizyne Technologies (IZTC), Ikena Oncology (IKNA), MediciNova (MNOV), Adaptimmune Therapeutics (ADAP), ImmuCell (ICCC), Viveon Health Acquisition (VHAQ), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors InterCure IGM Biosciences Immunic Invizyne Technologies Ikena Oncology MediciNova Adaptimmune Therapeutics ImmuCell Viveon Health Acquisition Clearside Biomedical Citius Pharmaceuticals (NASDAQ:CTXR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Do analysts prefer CTXR or INCR? Citius Pharmaceuticals currently has a consensus price target of $53.00, suggesting a potential upside of 2,646.11%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CTXR or INCR more profitable? InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -58.63% -37.67% InterCure N/A N/A N/A Which has higher valuation & earnings, CTXR or INCR? InterCure has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/AInterCure$64.55MN/A-$18.32MN/AN/A Which has more volatility & risk, CTXR or INCR? Citius Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CTXR or INCR? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor CTXR or INCR? In the previous week, Citius Pharmaceuticals had 5 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.33 indicating that InterCure is being referred to more favorably in the news media. Company Overall Sentiment Citius Pharmaceuticals Neutral InterCure Neutral SummaryCitius Pharmaceuticals beats InterCure on 8 of the 13 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.39M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.06%P/E RatioN/A8.9827.0020.10Price / SalesN/A729.50435.75120.29Price / CashN/A159.8036.8257.86Price / Book0.194.517.985.56Net Income-$39.14M$31.26M$3.16B$248.40M7 Day Performance1.58%5.57%3.69%6.04%1 Month Performance126.79%5.48%2.91%7.69%1 Year Performance-87.17%1.14%34.30%20.97% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.4183 of 5 stars$1.93-8.5%$53.00+2,646.1%-84.1%$22.39MN/A0.0020News CoverageINCRInterCureN/A$1.47-1.3%N/A-34.8%$66.99M$66.28M0.00350High Trading VolumeIGMSIGM Biosciences4.3971 of 5 stars$1.12+3.7%$5.50+391.1%-78.5%$66.95M$2.68M-0.34190IMUXImmunic2.7918 of 5 stars$0.70-0.4%$11.60+1,563.1%-29.2%$66.83MN/A-0.5770Positive NewsIZTCInvizyne TechnologiesN/A$10.39+6.8%N/AN/A$64.96MN/A0.0029Gap UpIKNAIkena Oncology2.7912 of 5 stars$1.34-1.5%$3.00+123.9%-18.7%$64.67M$9.16M-1.5670Positive NewsMNOVMediciNova1.832 of 5 stars$1.31-1.5%$7.00+434.4%-11.3%$64.26M$1M-5.7010Gap DownADAPAdaptimmune Therapeutics2.1081 of 5 stars$0.24-2.2%$1.35+463.9%-80.2%$63.53M$179.64M-0.89490Gap UpICCCImmuCell0.2911 of 5 stars$6.96+3.1%N/A+52.6%$62.92M$26.49M-99.4170VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeCLSDClearside Biomedical2.0335 of 5 stars$0.80+3.9%$4.75+493.8%-36.3%$62.17M$3.76M-1.9530News CoveragePositive News Related Companies and Tools Related Companies INCR Competitors IGMS Competitors IMUX Competitors IZTC Competitors IKNA Competitors MNOV Competitors ADAP Competitors ICCC Competitors VHAQ Competitors CLSD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts